Entering text into the input field will update the search result below

More Positive Amarin Developments This Week

Jul. 19, 2013 9:49 AM ETAMRN20 Comments
Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Growth, Value

Seeking Alpha Analyst Since 2012

While multiple followers have emailed me about some comments by someone named Jeerio re: FDA allowing JELIS data to be included when marketing Vascepa, I have no information to contribute whether that is fact or fiction. While it would seem positive, I would tread carefully with that information.

I will say I have been able to confirm that Vascepa will have expanded label data by end of this year, based on enrollment >50% for Reduce-It. This is very significant and if WallStreet actually got their heads out of their bums, the stock would trade up $3-5 on this expectation alone...

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.